Hemostemix (CVE:HEM) Trading Up 71.4% – Still a Buy?

Hemostemix Inc. (CVE:HEM) shares traded up 71.4% during trading on Tuesday . The stock traded as high as C$0.12 and last traded at C$0.12. 592,088 shares traded hands during trading, an increase of 516% from the average session volume of 96,162 shares. The stock had previously closed at C$0.07.

Hemostemix Stock Performance

The stock has a fifty day simple moving average of C$0.08 and a 200 day simple moving average of C$0.07. The firm has a market cap of C$9.58 million, a P/E ratio of -5.50 and a beta of 0.20.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.